12
Participants
Start Date
October 10, 2017
Primary Completion Date
May 30, 2019
Study Completion Date
August 23, 2024
TAA-specific CTLs
"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10\^7 cells/m2~Day 28: 2 x 10\^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
Houston Methodist Hospital, Houston
Smith Clinic - Harris Health System, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
National Cancer Institute (NCI)
NIH
Cancer Prevention Research Institute of Texas
OTHER
Baylor College of Medicine
OTHER